Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alfresa Fine Chemical is a Japanese pharmaceutical company specializing in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and diagnostic reagents. As a core subsidiary of Alfresa Holdings Corporation, the company operates as a Contract Development and Manufacturing Organization (CDMO), offering services from process development to commercial-scale production. Their technical expertise includes high-potency API (HPAPI) manufacturing and complex small molecule synthesis. The company maintains multiple GMP-compliant facilities in Japan, supporting a wide range of therapeutic areas including cardiovascular and central nervous system disorders. Alfresa Fine Chemical serves both domestic and international markets, providing critical chemical components for the global healthcare industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alfresa Fine Chemical.